University Of Pecs

The University of Pecs is conducting studies that aim to improve outcomes for patients with heart‑related conditions by evaluating innovative lipid‑lowering and blood‑pressure therapies.

• Familial hypercholesterolemia and lipoprotein(a) reduction
• Combination of vicadrostat with empagliflozin in type 2 diabetes and hypertension
• Long‑term safety of inclisiran for cholesterol management
• Assessment of major cardiovascular events in high‑risk populations
• Impact of novel agents on heart failure hospitalization rates

These trials seek to test new therapeutic approaches, reduce cardiovascular risk, and broaden treatment options for patients across Europe.

Research at the site focuses on advanced blood‑cancer therapies, exploring targeted treatments that aim to increase remission rates in acute lymphoblastic leukemia.

• Philadelphia‑positive B‑cell acute lymphoblastic leukemia
• ABL‑class Ph‑like B‑ALL with PDGFRB gene fusions
• Integration of blinatumomab with continuous tyrosine‑kinase inhibitors
• Safety profiling of novel chemo‑immunotherapy backbones
• Evaluation of event‑free survival in young adults

The goal is to evaluate treatment effectiveness and safety, offering hope for improved long‑term survival in these aggressive blood disorders.

The department is testing immune‑modulating agents to address severe autoimmune conditions, with an emphasis on both efficacy and tolerability.

• Upadacitinib for severe alopecia areata
• Lutikizumab in moderate to severe hidradenitis suppurativa
• MK‑7240/PRA023 for systemic sclerosis‑associated interstitial lung disease
• Baricitinib added to standard of care for immunocompromised COVID‑19 patients
• Long‑term safety monitoring of novel JAK inhibitors

These investigations aim to bring new therapeutic options to patients whose immune systems drive chronic disease.

Multiple oncology trials are underway, targeting a range of solid tumors with combination immunotherapies and precision medicines.

• Advanced melanoma treated with pembrolizumab‑based regimens
• PD‑L1‑positive head and neck squamous cell carcinoma
• Microsatellite‑instability‑high metastatic colorectal cancer
• Non‑small cell lung cancer evaluated with MK‑3475A combinations
• Evaluation of progression‑free and overall survival endpoints

The purpose of these studies is to assess the effectiveness of emerging therapies and improve survival outcomes for cancer patients.

Clinical research is directed at dermatologic and connective‑tissue disorders, seeking to validate new treatments that address both skin symptoms and underlying inflammation.

• Severe alopecia areata response to upadacitinib
• Hidradenitis suppurativa outcomes with lutikizumab
• Systemic sclerosis‑associated interstitial lung disease and forced vital capacity preservation
• Safety of long‑term biologic therapy in adolescent populations
• Impact on quality of life and disease severity scores

These trials focus on improving clinical signs, patient comfort, and long‑term disease management.

The site participates in pandemic‑response studies that evaluate therapeutic strategies for viral infections, particularly COVID‑19.

• Adaptive platform trial assessing treatments for moderate COVID‑19
• Severe and critical COVID‑19 mortality reduction with baricitinib
• Solidarity‑type multinational collaboration (SolidAct)
• Evaluation of antiviral efficacy and safety in hospitalized patients
• Monitoring of immunocompromised patient outcomes

The objective is to determine effective interventions that lessen disease progression and improve survival during viral outbreaks.